2025 United States Biobanking Market Revenue Opportunities Report
Description
The 2025 United States Biobanking Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biobanking Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States biobanking market are Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), Hamilton Company, and BD (Becton, Dickinson and Company). Thermo Fisher Scientific leads with extensive offerings in laboratory instruments, sample management systems, and software solutions tailored for biobanking, supported by annual revenues around USD 40 billion. Merck KGaA, through Sigma-Aldrich, provides comprehensive biobank solutions including reagents and equipment, with a strong global presence and revenues exceeding USD 60 billion. Hamilton Company specializes in advanced automation and sample storage systems critical to biobank operations. BD delivers end-to-end biobanking services focused on specimen collection, processing, and diagnostics, contributing significantly to personalized medicine research.
These companies are instrumental in supporting U.S. biobanking, which accounts for approximately 84.5% of North America's market share. Their products and services enable high-quality biospecimen preservation and data management, facilitating research in precision medicine, drug development, and clinical diagnostics. The U.S. biobanking sector benefits from strong government backing, including NIH funding and regulations like HIPAA, which ensure secure data handling. Collaboration among these companies, healthcare providers, and academic institutions is driving innovation, advancing genomics, and expanding biobanking infrastructure nationwide, further accelerated by emerging technologies such as AI and machine learning.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biobanking Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States biobanking market are Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), Hamilton Company, and BD (Becton, Dickinson and Company). Thermo Fisher Scientific leads with extensive offerings in laboratory instruments, sample management systems, and software solutions tailored for biobanking, supported by annual revenues around USD 40 billion. Merck KGaA, through Sigma-Aldrich, provides comprehensive biobank solutions including reagents and equipment, with a strong global presence and revenues exceeding USD 60 billion. Hamilton Company specializes in advanced automation and sample storage systems critical to biobank operations. BD delivers end-to-end biobanking services focused on specimen collection, processing, and diagnostics, contributing significantly to personalized medicine research.
These companies are instrumental in supporting U.S. biobanking, which accounts for approximately 84.5% of North America's market share. Their products and services enable high-quality biospecimen preservation and data management, facilitating research in precision medicine, drug development, and clinical diagnostics. The U.S. biobanking sector benefits from strong government backing, including NIH funding and regulations like HIPAA, which ensure secure data handling. Collaboration among these companies, healthcare providers, and academic institutions is driving innovation, advancing genomics, and expanding biobanking infrastructure nationwide, further accelerated by emerging technologies such as AI and machine learning.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
